Plain-English translation of NCT04635020 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing whether a tiny implant called iStent Trabecular Micro-bypass Stent works better than laser treatment for glaucoma when combined with cataract surgery. Both approaches aim to lower eye pressure in people with exfoliation glaucoma (a form of glaucoma caused by buildup of material in the eye). The study will help doctors decide which treatment works best for patients who need both procedures.
Exfoliation glaucoma can cause vision loss if eye pressure isn't controlled well. When patients need cataract surgery anyway, doctors want to know if adding a glaucoma treatment at the same time helps more than doing just the cataract surgery alone.
You likely qualify if…
You likely don't qualify if…
You will have cataract surgery combined with either a tiny implant placement or laser treatment — or cataract surgery alone (depending on your glaucoma stability). If you receive laser treatment, that will happen one month after your cataract surgery. You will attend follow-up visits over 12 months so doctors can check your eye pressure and vision to see which approach works best for you.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
Finland
Sponsor
Helsinki University Central Hospital
Enrollment target
~285 participants
Started
October 2020
Primary completion
September 2023
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
50 Years – 100 Years
Last updated on clinicaltrials.gov in November 2020.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Eeva Ojanen, MD
Helsinki University Central Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.